{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:13:02Z","timestamp":1762254782659,"version":"3.40.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.therap.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T16:18:26Z","timestamp":1708791506000},"page":"609-611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transmucosal fentanyl-related opioid use disorder in a cancer survivor"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8396-3667","authenticated-orcid":false,"given":"Salim","family":"Mezaache","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Cutarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Frauger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.02.002_bib0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/10717540500394661","article-title":"Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics","volume":"13","author":"Mystakidou","year":"2006","journal-title":"Drug Deliv"},{"key":"10.1016\/j.therap.2024.02.002_bib0060","doi-asserted-by":"crossref","first-page":"977","DOI":"10.6004\/jnccn.2019.0038","article-title":"Adult cancer pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Swarm","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.therap.2024.02.002_bib0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jpainsymman.2010.03.012","article-title":"Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain","volume":"41","author":"Passik","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.therap.2024.02.002_bib0070","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2019.11.002","article-title":"French trends in the misuse of fentanyl: from 2010 to 2015","volume":"75","author":"Tournebize","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.02.002_bib0075","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jpainsymman.2022.02.016","article-title":"The prevalence of off-label prescribing of transmucosal immediate-release fentanyl in France","volume":"63","author":"Guastella","year":"2022","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.therap.2024.02.002_bib0080","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.2019.0235","article-title":"Assessment of the FDA risk evaluation and mitigation strategy for transmucosal immediate-release fentanyl products","volume":"321","author":"Rollman","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2024.02.002_bib0085","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jpainsymman.2011.07.006","article-title":"Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain","volume":"42","author":"N\u00fa\u00f1ez-Olarte","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.therap.2024.02.002_bib0090","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/pme.12382","article-title":"Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse","volume":"15","author":"Granata","year":"2014","journal-title":"Pain Med"},{"key":"10.1016\/j.therap.2024.02.002_bib0095","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00228-017-2272-9","article-title":"High opioids tolerance due to transmucosal fentanyl abuse","volume":"73","author":"Eiden","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.02.002_bib0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpain.2014.01.494","article-title":"Methadone safety: a clinical practice guideline from the American Pain Society and College on problems of drug dependence, in collaboration with the Heart Rhythm Society","volume":"15","author":"Chou","year":"2014","journal-title":"J Pain"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T06:53:46Z","timestamp":1729320826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724000313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0040595724000313"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.02.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transmucosal fentanyl-related opioid use disorder in a cancer survivor","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}